

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Boill Healthcare Holdings Limited

保集健康控股有限公司

(Formerly known as “Ngai Shun Holdings Limited 毅信控股有限公司”)

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 01246)

TERMINATION OF THE DISCLOSABLE TRANSACTION IN RELATION TO ACQUISITION OF THE ENTIRE EQUITY INTEREST OF THE TARGET COMPANY

Reference is made to the announcement (the “**Announcement**”) of Boill Healthcare Holdings Limited (the “**Company**”) dated 30 October 2017 in relation to the entering into of the Equity Transfer Agreement. Capitalised terms used herein shall have the meanings as those defined in the Announcement unless the context otherwise requires. This announcement is made pursuant to Rule 14.36 of the Listing Rules.

TERMINATION AGREEMENT

On 22 December 2017, the parties to the Equity Transfer Agreement entered into a termination agreement (the “**Termination Agreement**”) to terminate the Equity Transfer Agreement with immediate effect. As at the date of this announcement, the Group has not made any or deposit or payment to the Vendor under the Equity Transfer Agreement. Upon execution of the Termination Agreement, all parties to the Equity Transfer Agreement shall be released and discharged from their respective obligations under the Equity Transfer Agreement.

The parties to the Equity Transfer Agreement decided not to proceed with the Acquisition due to commercial reasons such as the acquisition method after due and careful consideration of all circumstances regarding the Acquisition and then all agreed to enter into the Termination Agreement. The Board is of the view that the termination of the Equity Transfer Agreement does not have adverse impact on the business operations and financial position of the Group.

By order of the Board of
Boill Healthcare Holdings Limited
Dai Dong Xing
Executive Director and Chairman

Hong Kong, 22 December 2017

As at the date of this announcement, the Company has (i) four executive Directors, namely Mr. Dai Dong Xing, Mr. Mock Wai Yin, Dr. Wong Yun Kuen, and Mr. Zhang Sheng Hai; (ii) one non-executive Director, namely Mr. Chui Kwong Kau; and (iii) four independent non-executive Directors, namely Mr. Xu Liang Wei, Mr. Wang Zhe, Mr. Hua Shan and Mr. Chan Chi Keung, Billy.